China’s next drug-price reset runs on provincial clocks
Fujian’s new notice and Beijing’s rollout show separate price, procurement and payment switches. The 70% payment-standard rule also needs a floor—not a reimbursement shortcut.
Latest
China targets hospital formulary barriers for eligible innovative drugs
BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg
Charles River’s $470m Frontage purchase hinges on a take-private and a split
TYK is paying RMB 300 million so Qilu can sell a drug Huiyu says it already had.
Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.
Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.
Desk brief
China targets hospital formulary barriers for eligible innovative drugs
A four-agency notice addresses formulary limits, hospital performance metrics and payment exceptions for eligible innovative drugs. Uptake remains to be demonstrated.
BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg
Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.
Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.
China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.
AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA
HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA
Pipeline
BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg
BrightGene reports a 32-week HbA1c advantage for BGM0504 10 mg over semaglutide 1 mg. The diabetes program still needs a filing and approval.
Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.
Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.
Abbisko’s pimicotinib at FDA: reading the China-to-Merck path
AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA
HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA
Yili Pharma raises nearly RMB 400m Series A for radiopharma
Regulation
China’s next drug-price reset runs on provincial clocks
Fujian’s new notice and Beijing’s rollout show separate price, procurement and payment switches. The 70% payment-standard rule also needs a floor—not a reimbursement shortcut.
China targets hospital formulary barriers for eligible innovative drugs
China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.
Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open
Abbisko’s pimicotinib at FDA: reading the China-to-Merck path
